<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966978</url>
  </required_header>
  <id_info>
    <org_study_id>STU 072013-030</org_study_id>
    <nct_id>NCT01966978</nct_id>
  </id_info>
  <brief_title>The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study</brief_title>
  <acronym>SIMPLE</acronym>
  <official_title>The Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to assess and compare the effect of insulin detemir in
      combination with liraglutide and metformin versus insulin detemir in combination with insulin
      aspart and metformin in subjects with very uncontrolled Type 2 Diabetes (A1c &gt; 10%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare a GLP-1 plus basal insulin and metformin treatment
      regimen to a basal-bolus plus metformin treatment regimen in patients with very uncontrolled
      (HbA1c&gt;10%) type 2 diabetes. The investigators will compare the two regimens with respect to
      efficacy in improving glycemic control, rate of hypoglycemia, change in weight, effect on
      patient quality of life, treatment burden, physician time, as well as healthcare related
      cost. The investigators hypothesize that at 26 weeks from randomization the two treatment
      regimens will have similar percentage of patients reaching A1c levels &lt;7.0%, while more
      patients on the GLP-1 plus basal insulin strategy will achieve the composite end point of A1c
      levels &lt;7.0% without severe hypoglycemia or significant weight gain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Randomization in A1c at Week 26</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Change in glycosylated Hemoglobin A1c (A1c) from randomization to 26 weeks of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite End-point</measure>
    <time_frame>Week 0 (Randomization) , Week 26</time_frame>
    <description>Percentage of participants with glycosylated Hemoglobin A1c (A1c)&lt;8% AND no documented severe hypoglycemia (&lt;56 mg/dL) during the study AND no significant weight gain (&gt;3% from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reaching Target A1c of &lt;7% at Week 26</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reaching Pre-specified &quot;Treatment Failure&quot; Outcome</measure>
    <time_frame>week 13</time_frame>
    <description>Treatment Failure defined as A1c&gt;10% at week 13 (visit 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Randomization in Body Weight</measure>
    <time_frame>Week 0 (Randomization) , Week 26</time_frame>
    <description>Change in body weight from randomization to end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Episodes</measure>
    <time_frame>Week 0 (Randomization) , Week 2, week 4, week 13, Week 26</time_frame>
    <description>Percentage of participants experiencing any episodes of documented hypoglycemia defined as CBG reading of &lt;70 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetes Quality of Life (DQOL)Questionnaire Score- Least Squares Means</measure>
    <time_frame>Week 0 (Randomization) , Week 26</time_frame>
    <description>Diabetes Quality of Life (DQOL) questionnaires will be completed by the patient at the randomization and end-of study visits. ALL D-QOL domains are scored on a 1-5 scale, with a lower number representing better quality of life or treatment satisfaction. Outcome reported is difference between mean baseline and mean Week 26 score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36) Questionnaire Score</measure>
    <time_frame>Week 0 (Randomization) , Week 26</time_frame>
    <description>Quality of life questionnaires will be completed by the patient at the randomization and end-of study visits. SF-36 is scored on a 1-100 scale; a higher score represents a better self-assessed health - for all domains.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Control: Metformin, Insulin Detemir, Insulin Aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin, insulin determir, Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)</description>
    <arm_group_label>Control: Metformin, Insulin Detemir, Insulin Aspart</arm_group_label>
    <arm_group_label>Metformin, insulin determir, Liraglutide</arm_group_label>
    <other_name>Metformin tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir</intervention_name>
    <description>Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.</description>
    <arm_group_label>Control: Metformin, Insulin Detemir, Insulin Aspart</arm_group_label>
    <arm_group_label>Metformin, insulin determir, Liraglutide</arm_group_label>
    <other_name>Insulin Detemir subcutaneous once or twice daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
    <arm_group_label>Metformin, insulin determir, Liraglutide</arm_group_label>
    <other_name>Liraglutide 6 mg/mL Subcutaneously</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
    <arm_group_label>Control: Metformin, Insulin Detemir, Insulin Aspart</arm_group_label>
    <other_name>Insulin Aspart Subcutaneous injection one to three times daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Clinical diagnosis of type 2 diabetes with confirmed HbA1c level &gt;10% at time of
        enrollment, regardless of prior or current treatment regimens, or time since diagnosis.

        Exclusion Criteria:

          1. Age &lt;18 as the feasibility and safety of this treatment regimen should be first
             established in the adult population; if successful, a subsequent pediatric study will
             be proposed;

          2. Type 1 diabetes as purposefully withholding meal-time insulin is contraindicated;

          3. Clinical state requiring inpatient admission/treatment;

          4. Contraindication or strong cautions to any of the study medications:

               1. Creatinine above 1.4 mg/dl for women and 1.5 mg/dl for men (per metformin label)

               2. History of lactic acidosis (per metformin label)

               3. Advanced hepatic or cardiac disease (per metformin label)

               4. Age &gt;80 years (per metformin label)

               5. Chronic alcohol use (&gt;14 drinks/week)

               6. History of pancreatitis (per liraglutide label)

               7. Personal or family history of medullary thyroid cancer or MEN syndrome (per
                  liraglutide label)

               8. Pregnancy and lactation (per liraglutide label)

          5. Any serious or unstable medical condition as it would interfere with treatment
             assignment as well as outcome measurement;

          6. Any scheduled elective procedures/surgeries;

          7. Active infections, including osteomyelitis;

          8. Not willing to participate, unable to keep projected appointments, unwillingness to
             receive injectable treatment; unwillingness to perform 7-point glucose profiles over 2
             consecutive days the weeks prior to Randomization (visit 1)and the week prior to visit
             6

          9. Non English speaking.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ildiko Lingvay</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <results_first_submitted>August 12, 2019</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ildiko Lingvay</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Insulin</keyword>
  <keyword>Insulin, Long-Acting</keyword>
  <keyword>Insulin, Short Acting</keyword>
  <keyword>Detemir</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Glucagon Like Peptide</keyword>
  <keyword>Metformin</keyword>
  <keyword>Uncontrolled Diabetes</keyword>
  <keyword>Elevated A1c</keyword>
  <keyword>Incretins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT01966978/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total number of subjects consented is 157, total number of subjects randomized is 120, of those 120 only 110 are MITT data set</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
          <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
        </group>
        <group group_id="P2">
          <title>Metformin, Insulin Determir, Liraglutide</title>
          <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
          <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
        </group>
        <group group_id="B2">
          <title>Metformin, Insulin Determir, Liraglutide</title>
          <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="10.0"/>
                    <measurement group_id="B2" value="46.7" spread="9.0"/>
                    <measurement group_id="B3" value="47.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.0" spread="1.5"/>
                    <measurement group_id="B2" value="12.1" spread="1.4"/>
                    <measurement group_id="B3" value="12.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Randomization in A1c at Week 26</title>
        <description>Change in glycosylated Hemoglobin A1c (A1c) from randomization to 26 weeks of therapy</description>
        <time_frame>Baseline and Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Randomization in A1c at Week 26</title>
          <description>Change in glycosylated Hemoglobin A1c (A1c) from randomization to 26 weeks of therapy</description>
          <units>Percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.4" upper_limit="3.7"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite End-point</title>
        <description>Percentage of participants with glycosylated Hemoglobin A1c (A1c)&lt;8% AND no documented severe hypoglycemia (&lt;56 mg/dL) during the study AND no significant weight gain (&gt;3% from baseline)</description>
        <time_frame>Week 0 (Randomization) , Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Composite End-point</title>
          <description>Percentage of participants with glycosylated Hemoglobin A1c (A1c)&lt;8% AND no documented severe hypoglycemia (&lt;56 mg/dL) during the study AND no significant weight gain (&gt;3% from baseline)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reaching Target A1c of &lt;7% at Week 26</title>
        <time_frame>Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reaching Target A1c of &lt;7% at Week 26</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reaching Pre-specified &quot;Treatment Failure&quot; Outcome</title>
        <description>Treatment Failure defined as A1c&gt;10% at week 13 (visit 5)</description>
        <time_frame>week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reaching Pre-specified &quot;Treatment Failure&quot; Outcome</title>
          <description>Treatment Failure defined as A1c&gt;10% at week 13 (visit 5)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Randomization in Body Weight</title>
        <description>Change in body weight from randomization to end of study.</description>
        <time_frame>Week 0 (Randomization) , Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Randomization in Body Weight</title>
          <description>Change in body weight from randomization to end of study.</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.7" upper_limit="4.6"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-0.9" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Episodes</title>
        <description>Percentage of participants experiencing any episodes of documented hypoglycemia defined as CBG reading of &lt;70 mg/dl</description>
        <time_frame>Week 0 (Randomization) , Week 2, week 4, week 13, Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Episodes</title>
          <description>Percentage of participants experiencing any episodes of documented hypoglycemia defined as CBG reading of &lt;70 mg/dl</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1"/>
                    <measurement group_id="O2" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diabetes Quality of Life (DQOL)Questionnaire Score- Least Squares Means</title>
        <description>Diabetes Quality of Life (DQOL) questionnaires will be completed by the patient at the randomization and end-of study visits. ALL D-QOL domains are scored on a 1-5 scale, with a lower number representing better quality of life or treatment satisfaction. Outcome reported is difference between mean baseline and mean Week 26 score.</description>
        <time_frame>Week 0 (Randomization) , Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diabetes Quality of Life (DQOL)Questionnaire Score- Least Squares Means</title>
          <description>Diabetes Quality of Life (DQOL) questionnaires will be completed by the patient at the randomization and end-of study visits. ALL D-QOL domains are scored on a 1-5 scale, with a lower number representing better quality of life or treatment satisfaction. Outcome reported is difference between mean baseline and mean Week 26 score.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Health Perception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.6" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.1" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Health Perception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.9" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-1.5" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.5" upper_limit="-0.04"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-0.8" upper_limit="-0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Related Worry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.4" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social or Vocational Worry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.3" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.4" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia Fear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.04" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.4" upper_limit="-0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycemic Control Perception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-1.6" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-2.0" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with Insulin Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.8" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-2.2" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Willingness to Continue Insulin Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-1.4" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-1.7" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LifeStyle Flexibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" lower_limit="-0.4" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.4" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Stigma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.2" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form-36 (SF-36) Questionnaire Score</title>
        <description>Quality of life questionnaires will be completed by the patient at the randomization and end-of study visits. SF-36 is scored on a 1-100 scale; a higher score represents a better self-assessed health - for all domains.</description>
        <time_frame>Week 0 (Randomization) , Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
            <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
          </group>
          <group group_id="O2">
            <title>Metformin, Insulin Determir, Liraglutide</title>
            <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form-36 (SF-36) Questionnaire Score</title>
          <description>Quality of life questionnaires will be completed by the patient at the randomization and end-of study visits. SF-36 is scored on a 1-100 scale; a higher score represents a better self-assessed health - for all domains.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.4" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.007" lower_limit="-0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.1" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-0.02" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months (Baseline to Week 26)</time_frame>
      <desc>Adverse events were collected both by self-report as well as review of the electronic health record. Nausea, vomiting, headache, diarrhea and abdominal pain were pre-defined events of special interest and proactively elicited at each visit from all patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control: Metformin, Insulin Detemir, Insulin Aspart</title>
          <description>Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Insulin Aspart: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG &lt;180</description>
        </group>
        <group group_id="E2">
          <title>Metformin, Insulin Determir, Liraglutide</title>
          <description>Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol&quot;; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)
Metformin: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
Detemir: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
Liraglutide: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vitreal hemmorhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Lower GI bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>puncture wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>nasopharyngeal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric inpatient hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other AE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ildiko Lingvay</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-2779</phone>
      <email>ildiko.lingvay@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

